

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

CD20 Antibody, anti-human, PE-Vio® 770, REAfinity™

RRID:AB_2656074

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-111-340, RRID:AB_2656074

Antibody Information

URL: http://antibodyregistry.org/AB_2656074

Proper Citation: Miltenyi Biotec Cat# 130-111-340, RRID:AB_2656074

Target Antigen: CD20

Host Organism: human

Clonality: monoclonal

Comments: Applications: MACS Flow Cytometry

Antigen Distribution: B cells, cancer stem cells, dendritic cells, lymphocytes

Antibody Name: CD20 Antibody, anti-human, PE-Vio® 770, REAfinity™

Description: This monoclonal targets CD20

Target Organism: human

Clone ID: clone REA780

Antibody ID: AB_2656074

Vendor: Miltenyi Biotec

Catalog Number: 130-111-340

Record Creation Time: 20231110T034429+0000

Record Last Update: 20260901T005200+0000

Ratings and Alerts

No rating or validation information has been found for CD20 Antibody, anti-human, PE-Vio® 770, REAfinity™.

No alerts have been found for CD20 Antibody, anti-human, PE-Vio® 770, REAfinity™.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Desveaux JM, et al. (2026) Neutralizing human monoclonal antibodies that target the PcrV component of the type III secretion system of *Pseudomonas aeruginosa* act through distinct mechanisms. *eLife*, 14.

Lê H, et al. (2023) In vitro vascularized immunocompetent patient-derived model to test cancer therapies. *iScience*, 26(10), 108094.

Lundtoft C, et al. (2020) Function of multiple sclerosis-protective HLA class I alleles revealed by genome-wide protein-quantitative trait loci mapping of interferon signalling. *PLoS genetics*, 16(10), e1009199.